# EDGAR Filing Document

**Accession Number:** 0001585364
**File Stem:** 0001585364-26-000091
**Filing Date:** 2026-6
**Character Count:** 4370
**Document Hash:** dddb7e8132bc86afe7c2a5abafc15ea6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001585364-26-000091.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001585364-26-000091

**CONFORMED SUBMISSION TYPE**: SD

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERRIGO Co plc
- **CENTRAL INDEX KEY:** 0001585364
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SD
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36353
- **FILM NUMBER:** 261085963

**BUSINESS ADDRESS:**
- **STREET 1:** THE SHARP BUILDING
- **STREET 2:** HOGAN PLACE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 TY74
- **BUSINESS PHONE:** 269-673-8451

**MAIL ADDRESS:**
- **STREET 1:** 515 EASTERN AVENUE
- **CITY:** ALLEGAN
- **STATE:** MI
- **ZIP:** 49010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PERRIGO Co Ltd
- **DATE OF NAME CHANGE:** 20130828

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM SD** 

**Specialized Disclosure Report** 

**PERRIGO COMPANY PLC** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Ireland** | **001-36353** | **Not Applicable** |
| **(State or other jurisdiction** | **(Commission** | **(IRS Employer** |
| **of incorporation or organization)** | **File Number)** | **Identification No.)** |
| **The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74** | **The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74** | **Not Applicable** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**Charles Atkinson, telephone: +353 1 7094000** 

 **(Name and telephone number, including area code, of the person to contact in connection with this report.)** 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

⌧ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

------

**Section 1 - Conflict Minerals Disclosure** 

**Item 1.01 Conflict Minerals Disclosure and Report.** 

**Conflict Minerals Disclosure**

As required by Rule 13p-1 of the Securities Exchange Act of 1934, Perrigo Company plc ("the Company") conducted a review of its products to determine whether any conflict minerals (Cassiterite, Columbite-Tantalite, Wolframite, Gold, or their derivatives tantalum, tin and tungsten) are necessary to the functionality or production of those products. As part of this review, the Company's procurement, quality control, engineering, research and development and other groups reviewed bills of materials and queried suppliers to determine whether the Company's products possibly include conflict minerals. The Company determined that, for the period from January 1 through December 31, 2025, tin and tantalum were used in the internal components of certain electronic toothbrushes within the Oral Care product category and gold was used in pregnancy tests within the Women's Health category.

The Company conducted a reasonable country of origin inquiry with these suppliers, and each supplier provided written assurance that the tin, gold and tantalum did not originate from the Democratic Republic of the Congo or its adjoining countries.

This information is also publicly available at the Company's website at <u>www.perrigo.com</u>. The content of any website referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

---

| | | |
|:---|:---|:---|
| PERRIGO COMPANY PLC | PERRIGO COMPANY PLC |  |
| By: | /s/ Charles Atkinson | June 11, 2026 |
|  |  | (Date) |
| Name: Charles Atkinson | Name: Charles Atkinson |  |
| Title: Executive Vice President, General Counsel and Secretary | Title: Executive Vice President, General Counsel and Secretary |  |

---

<br>